Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 26,000 shares, a decrease of 72.3% from the September 30th total of 93,900 shares. Based on an average daily volume of 72,900 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.5% of the company’s stock are short sold.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Saturday, October 19th. They set a “sell” rating for the company.
Check Out Our Latest Stock Analysis on EVOK
Evoke Pharma Price Performance
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The company had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- The 3 Best Fintech Stocks to Buy Now
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the Nasdaq? Complete Overview with History
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- About the Markup Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.